FDA Compounding Crackdown Accelerates: 503B Window Closing, 16 New GLP-1 Drugs Expected by 2029

In a decisive move that signals the permanent closure of the lucrative GLP-1 compounding era, the U.S. FDA announced a proposed rule on April 30, 2026 (published in the Federal Register on May 1, 2026) to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B outsourcing facility bulk drug substances (bulks) list.

The FDA's proposal rests on a formal determination that there is no clinical need for outsourcing facilities to compound any of these three blockbuster GLP-1 agents from bulk drug substances under section 503B of the FD&C Act. If finalized after the public comment period (which runs through June 29, 2026), the rule will permanently foreclose any future compounding pathway for these agents, removing both the bulks-list and shortage-list pathways even in the event of new supply shortages.

The Rise and Fall of Compounded GLP-1 Copies

Skyrocketing demand for GLP-1 receptor agonists outpaced brand-name manufacturing capacity in 2022, leading to semaglutide, tirzepatide, and liraglutide being placed on the FDA's drug shortage list. This designation legally permitted 503A compounding pharmacies and 503B outsourcing facilities to compound copies of these drugs. Telehealth firms and digital clinics quickly pivoted to offer compounded GLP-1s at $150 to $300 per month, compared to brand-name costs exceeding $1,000 per month.

However, the FDA systematically resolved these shortages, declaring the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved in February 2025. Phased enforcement deadlines required compounders to wind down operations. Legal challenges by the Outsourcing Facilities Association failed to secure preliminary injunctions, solidifying that compounding "essentially a copy" of commercially available semaglutide or tirzepatide is no longer legally permissible.

Mounting Safety Concerns

The FDA's strict regulatory posture has been heavily informed by post-marketing safety data. As of early 2025, the agency had received:

• Over 455 adverse event reports linked to compounded semaglutide.
• Over 320 adverse event reports associated with compounded tirzepatide.

Many of these cases involved severe dosing errors because patients self-administered incorrect amounts from multidose vials, with some requiring hospitalization. The FDA also highlighted ongoing risks of counterfeit and substandard products entering the market via online channels.

Verbatim Quotes and Interpretation

"When FDA-approved drugs are available, outsourcing facilities cannot lawfully compound using bulk drug substances unless there is a clear clinical need. This action reflects our responsibility to protect patients and preserve the integrity of the drug approval process,” stated FDA Commissioner Marty Makary, MD, MPH, in the agency's news release.

"The agency's proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List signals that large-scale compounding of these agents has no regulatory future, and carries immediate implications for pharmacy practice," noted associate editor Luke Halpern in Pharmacy Times.

Investor and Telehealth Outlook

The elimination of the compounding pathway represents a severe structural threat to telehealth companies whose business models became heavily reliant on compounded GLP-1 copies. With the FDA shutting down large-scale compounding, digital health firms must transition patients to brand-name drugs, help them navigate manufacturer savings programs, or shift toward next-generation candidates.

Meanwhile, the pipeline continues to expand. At least 16 new GLP-1 drugs from competitors are expected to reach the market by 2029, which will eventually introduce genuine, FDA-approved generic competition and lower prices.